08 Nov 2021 --- Obese adults treated with Novo Nordisk’s Wegovy – a 2.4 mg subcutaneous injection of semaglutide – achieved significant and sustained weight loss over a two-year study period. With participants able to keep the weight off, researchers hope the substance will help treat and manage obesity as a chronic disease. Semaglutide is an analog of the human glucagon-like peptide-1 (GLP-1) hormone, with 94% similarity to the native human GLP-1 molecule. It induces weight loss by reducing hunger, increasing feeling of fullness and thereby helping people eat less and reduce their food cravings.
